<p>Kodiak Sciences Inc.（納斯達克代碼：KOD - 獲取免費報告）在週一交易前因內部人士購買活動而股價跳漲。該股票此前收於 26.00 美元，但開盤價為 27.95 美元。Kodiak Sciences 的股票最後交易價格為 28.2410 美元，成交量為 141,605 股。</p>
<p>獲取 <strong>Kodiak Sciences</strong> 的提醒：</p>
<p>具體來説，董事 Bros. Advisors Lp Baker 在 12 月 18 日（星期四）的一筆交易中購買了 2,608,696 股該股票。這些股票的平均購買價格為每股 23.00 美元，總價值為 60,000,008.00 美元。收購後，該董事直接持有公司 18,358,772 股股票，價值 422,251,756 美元。這代表其持股比例增加了 16.56%。該交易已在與 SEC 的法律文件中披露，相關信息可通過 SEC 網站訪問。</p>
<h2>分析師設定新目標價</h2>
<p>幾家券商對 KOD 發佈了報告。Weiss Ratings 在 10 月 8 日（星期三）的一份研究報告中重申了對 Kodiak Sciences 股票的 “賣出（e+）” 評級。Lifesci Capital 在 10 月 23 日（星期四）的一份研究報告中開始覆蓋 Kodiak Sciences 股票。他們給予該公司的 “跑贏大盤” 評級，並設定了 40.00 美元的目標價。摩根大通在 10 月 24 日（星期五）的一份研究報告中將 Kodiak Sciences 的評級從 “中性” 上調至 “增持”，並將其目標價從 15.00 美元提高至 24.00 美元。Chardan Capital 在 11 月 17 日（星期一）的一份研究報告中重申了 “中性” 評級，並設定了 14.00 美元的目標價。最後，華爾街 Zen 在 10 月 11 日（星期六）的一份報告中將 Kodiak Sciences 的評級從 “持有” 下調至 “賣出”。四位股票研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，共識目標價為 22.67 美元。</p>
<p><strong>查看我們對 KOD 的最新分析</strong></p>
<h2>Kodiak Sciences 股票表現</h2>
<p>該公司的市值為 14.6 億美元，市盈率為-6.85，貝塔值為 2.68。該公司的 50 日移動平均線為 20.38 美元，200 日移動平均線為 12.43 美元。</p>
<p>Kodiak Sciences（納斯達克代碼：KOD - 獲取免費報告）最後一次發佈財報是在 11 月 13 日（星期四）。該公司報告的每股收益為（1.16 美元），低於分析師的共識預期（1.07 美元）0.09 美元。股票分析師預計 Kodiak Sciences Inc.在當前財政年度將發佈-3.45 的每股收益。</p>
<h2>Kodiak Sciences 的機構交易</h2>
<p>幾家對沖基金和其他機構投資者最近買賣了該股票的股份。Headlands Technologies LLC 在第二季度將其在 Kodiak Sciences 的持股比例提高了 256.4%。Headlands Technologies LLC 現在擁有 8,083 股該公司的股票，價值 30,000 美元，此前在上個季度又購買了 5,815 股。Walleye Capital LLC 在第一季度收購了 Kodiak Sciences 的新股份，價值約 49,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度將其在 Kodiak Sciences 的持股比例提高了 21.7%。Vanguard Personalized Indexing Management LLC 現在擁有 15,070 股該公司的股票，價值 56,000 美元，此前在此期間又購買了 2,691 股。Russell Investments Group Ltd.在第一季度將其在 Kodiak Sciences 的持股比例提高了 729.9%。Russell Investments Group Ltd.現在擁有 21,039 股該公司的股票，價值 59,000 美元，此前在上個季度又收購了 18,504 股。最後，Dynamic Technology Lab Private Ltd 在第一季度收購了 Kodiak Sciences 的新股份，價值 94,000 美元。89.06% 的股票由機構投資者和對沖基金持有。</p>
<h2>Kodiak Sciences 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Kodiak Sciences, Inc 是一家總部位於加利福尼亞州帕洛阿爾託的臨牀階段生物製藥公司，專注於新型視網膜疾病療法的發現和開發。該公司的專有技術集中在抗體生物聚合物結合物（ABCs）上，旨在延長耐久性、增強組織滲透性並改善現有治療方式的安全性。Kodiak 的研發工作針對濕性年齡相關性黃斑變性（濕性 AMD）、糖尿病性黃斑水腫（DME）和其他嚴重眼科疾病。</p>
<p>Kodiak 研發管道中的主要產品候選是 KSI-301，一種通過玻璃體內注射給藥的抗 VEGF 抗體生物聚合物結合物。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票比 Kodiak Sciences 更好</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>100 萬美元在退休後能維持多久？</li>
<li>在 2026 年 1 月 1 日之前購買這隻 2 美元的黃金股票</li>
<li>“客户銀行存款 660 億美元面臨風險”</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Kodiak Sciences 嗎？</h2>
<p>在你考慮 Kodiak Sciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Kodiak Sciences 並不在名單上。</p>
<p>雖然 Kodiak Sciences 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

<p>Kodiak Sciences（納斯達克代碼：KOD）股價因內部人士買入活動而上漲。董事會顧問公司 Bros. Advisors Lp 的 Baker 以每股 23.00 美元購買了 2,608,696 股，總計 6000 萬美元。該股票開盤價為 27.95 美元，較前一交易日的 26.00 美元上漲，最後交易價為 28.2410 美元。分析師對該股票的評級不一，普遍評級為 “持有”，目標價為 22.67 美元。Kodiak Sciences 專注於視網膜疾病的治療，其主要產品候選藥物為 KSI-301</p>

<p>Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) gapped up prior to trading on Monday following insider buying activity. The stock had previously closed at $26.00, but opened at $27.95. Kodiak Sciences shares last traded at $28.2410, with a volume of 141,605 shares trading hands.</p>
<div class="lb-trans"><p>Kodiak Sciences Inc.（納斯達克代碼：KOD - 獲取免費報告）在週一交易前因內部人士購買活動而股價跳漲。該股票此前收於 26.00 美元，但開盤價為 27.95 美元。Kodiak Sciences 的股票最後交易價格為 28.2410 美元，成交量為 141,605 股。</p>
</div><p>Get <strong>Kodiak Sciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Kodiak Sciences</strong> 的提醒：</p>
</div><p>Specifically, Director Bros. Advisors Lp Baker bought 2,608,696 shares of the stock in a transaction on Thursday, December 18th. The shares were purchased at an average price of $23.00 per share, with a total value of $60,000,008.00. Following the acquisition, the director directly owned 18,358,772 shares of the company's stock, valued at $422,251,756. This represents a 16.56% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>具體來説，董事 Bros. Advisors Lp Baker 在 12 月 18 日（星期四）的一筆交易中購買了 2,608,696 股該股票。這些股票的平均購買價格為每股 23.00 美元，總價值為 60,000,008.00 美元。收購後，該董事直接持有公司 18,358,772 股股票，價值 422,251,756 美元。這代表其持股比例增加了 16.56%。該交易已在與 SEC 的法律文件中披露，相關信息可通過 SEC 網站訪問。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several brokerages have issued reports on KOD. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Kodiak Sciences in a research report on Wednesday, October 8th. Lifesci Capital initiated coverage on shares of Kodiak Sciences in a research report on Thursday, October 23rd. They issued an &#34;outperform&#34; rating and a $40.00 target price for the company. JPMorgan Chase &amp; Co. raised Kodiak Sciences from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and increased their price target for the company from $15.00 to $24.00 in a research report on Friday, October 24th. Chardan Capital restated a &#34;neutral&#34; rating and set a $14.00 target price on shares of Kodiak Sciences in a research report on Monday, November 17th. Finally, Wall Street Zen downgraded Kodiak Sciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, October 11th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $22.67.</p>
<div class="lb-trans"><p>幾家券商對 KOD 發佈了報告。Weiss Ratings 在 10 月 8 日（星期三）的一份研究報告中重申了對 Kodiak Sciences 股票的 “賣出（e+）” 評級。Lifesci Capital 在 10 月 23 日（星期四）的一份研究報告中開始覆蓋 Kodiak Sciences 股票。他們給予該公司的 “跑贏大盤” 評級，並設定了 40.00 美元的目標價。摩根大通在 10 月 24 日（星期五）的一份研究報告中將 Kodiak Sciences 的評級從 “中性” 上調至 “增持”，並將其目標價從 15.00 美元提高至 24.00 美元。Chardan Capital 在 11 月 17 日（星期一）的一份研究報告中重申了 “中性” 評級，並設定了 14.00 美元的目標價。最後，華爾街 Zen 在 10 月 11 日（星期六）的一份報告中將 Kodiak Sciences 的評級從 “持有” 下調至 “賣出”。四位股票研究分析師對該股票給予了買入評級，兩位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該股票目前的共識評級為 “持有”，共識目標價為 22.67 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on KOD</strong></p>
<div class="lb-trans"><p><strong>查看我們對 KOD 的最新分析</strong></p>
</div><h2>Kodiak Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Kodiak Sciences 股票表現</h2>
</div><p>The company has a market cap of $1.46 billion, a price-to-earnings ratio of -6.85 and a beta of 2.68. The company has a fifty day moving average of $20.38 and a two-hundred day moving average of $12.43.</p>
<div class="lb-trans"><p>該公司的市值為 14.6 億美元，市盈率為-6.85，貝塔值為 2.68。該公司的 50 日移動平均線為 20.38 美元，200 日移動平均線為 12.43 美元。</p>
</div><p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.09). Equities analysts expect that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Kodiak Sciences（納斯達克代碼：KOD - 獲取免費報告）最後一次發佈財報是在 11 月 13 日（星期四）。該公司報告的每股收益為（1.16 美元），低於分析師的共識預期（1.07 美元）0.09 美元。股票分析師預計 Kodiak Sciences Inc.在當前財政年度將發佈-3.45 的每股收益。</p>
</div><h2>Institutional Trading of Kodiak Sciences</h2>
<div class="lb-trans"><h2>Kodiak Sciences 的機構交易</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC boosted its position in shares of Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock worth $30,000 after purchasing an additional 5,815 shares in the last quarter. Walleye Capital LLC acquired a new stake in shares of Kodiak Sciences during the 1st quarter worth approximately $49,000. Vanguard Personalized Indexing Management LLC lifted its holdings in Kodiak Sciences by 21.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after purchasing an additional 2,691 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Kodiak Sciences by 729.9% in the 1st quarter. Russell Investments Group Ltd. now owns 21,039 shares of the company's stock worth $59,000 after acquiring an additional 18,504 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Kodiak Sciences during the first quarter valued at $94,000. 89.06% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買賣了該股票的股份。Headlands Technologies LLC 在第二季度將其在 Kodiak Sciences 的持股比例提高了 256.4%。Headlands Technologies LLC 現在擁有 8,083 股該公司的股票，價值 30,000 美元，此前在上個季度又購買了 5,815 股。Walleye Capital LLC 在第一季度收購了 Kodiak Sciences 的新股份，價值約 49,000 美元。Vanguard Personalized Indexing Management LLC 在第二季度將其在 Kodiak Sciences 的持股比例提高了 21.7%。Vanguard Personalized Indexing Management LLC 現在擁有 15,070 股該公司的股票，價值 56,000 美元，此前在此期間又購買了 2,691 股。Russell Investments Group Ltd.在第一季度將其在 Kodiak Sciences 的持股比例提高了 729.9%。Russell Investments Group Ltd.現在擁有 21,039 股該公司的股票，價值 59,000 美元，此前在上個季度又收購了 18,504 股。最後，Dynamic Technology Lab Private Ltd 在第一季度收購了 Kodiak Sciences 的新股份，價值 94,000 美元。89.06% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Kodiak Sciences Company Profile</h2>
<div class="lb-trans"><h2>Kodiak Sciences 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.</p>
<div class="lb-trans"><p>Kodiak Sciences, Inc 是一家總部位於加利福尼亞州帕洛阿爾託的臨牀階段生物製藥公司，專注於新型視網膜疾病療法的發現和開發。該公司的專有技術集中在抗體生物聚合物結合物（ABCs）上，旨在延長耐久性、增強組織滲透性並改善現有治療方式的安全性。Kodiak 的研發工作針對濕性年齡相關性黃斑變性（濕性 AMD）、糖尿病性黃斑水腫（DME）和其他嚴重眼科疾病。</p>
</div><p>The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.</p>
<div class="lb-trans"><p>Kodiak 研發管道中的主要產品候選是 KSI-301，一種通過玻璃體內注射給藥的抗 VEGF 抗體生物聚合物結合物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Kodiak Sciences</li>
<li>Wall Street Stock picker Names #1 Stock of 2026</li>
<li>Do not delete, read immediately</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>Buy this $2 Gold Stock Before January 1, 2026</li>
<li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Kodiak Sciences 更好</li>
<li>華爾街股票挑選者命名 2026 年第一隻股票</li>
<li>請勿刪除，立即閲讀</li>
<li>100 萬美元在退休後能維持多久？</li>
<li>在 2026 年 1 月 1 日之前購買這隻 2 美元的黃金股票</li>
<li>“客户銀行存款 660 億美元面臨風險”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Kodiak Sciences 嗎？</h2>
</div><p>Before you consider Kodiak Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Kodiak Sciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Kodiak Sciences 並不在名單上。</p>
</div><p>While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Kodiak Sciences 目前在分析師中獲得了持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Kodiak Sciences (NASDAQ:KOD) 的股價在內部人士買入活動後出現跳空上漲